Next Article in Journal
Snack Food Consumption across the Pune Transect in India: A Comparison of Dietary Behaviors Based on Consumer Characteristics and Locations
Next Article in Special Issue
Nutrition in Gynecologic Disease
Previous Article in Journal
Dietary Antioxidant Capacity Promotes a Protective Effect against Exacerbated Oxidative Stress in Women Undergoing Adjuvant Treatment for Breast Cancer in a Prospective Study
Previous Article in Special Issue
Supplementation with Spirulina platensis Prevents Uterine Diseases Related to Muscle Reactivity and Oxidative Stress in Rats Undergoing Strength Training
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 13
Issue 12
10.3390/nu13124326
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Phytoprogestins: Unexplored Food Compounds with Potential Preventive and Therapeutic Effects in Female Diseases

by
Stefania Greco
1,
Pamela Pellegrino
1,
Alessandro Zannotti
1,2,
Giovanni Delli Carpini
2,
Andrea Ciavattini
2,
Fernando M. Reis
3 and
Pasquapina Ciarmela
1,*
1
Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy
2
Department of Specialist and Odontostomatological Clinical Sciences, Università Politecnica delle Marche, 60126 Ancona, Italy
3
Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil
*
Author to whom correspondence should be addressed.
Nutrients 2021, 13(12), 4326; https://doi.org/10.3390/nu13124326
Submission received: 4 November 2021 / Revised: 25 November 2021 / Accepted: 29 November 2021 / Published: 30 November 2021
(This article belongs to the Special Issue Nutrition in Gynecologic Disease)
Browse Figures
Versions Notes

Abstract

:
In recent years, there has been an increasing interest in natural therapies to prevent or treat female diseases. In particular, many studies have focused on searching natural compounds with less side effects than standard hormonal therapies. While phytoestrogen-based therapies have been extensively studied, treatments with phytoprogestins reported in the literature are very rare. In this review, we focused on compounds of natural origin, which have progestin effects and that could be good candidates for preventing and treating female diseases. We identified the following phytoprogestins: kaempferol, apigenin, luteolin, and naringenin. In vitro studies showed promising results such as the antitumoral effects of kaempferol, apigenin and luteolin, and the anti-fibrotic effects of naringenin. Although limited data are available, it seems that phytoprogestins could be a promising tool for preventing and treating hormone-dependent diseases.

1. Introduction

In recent years, there has been an increasing interest in alternative and natural methods for the prevention or treatment of female diseases. In particular, many studies have focused on searching for adequate compounds with less side effects than standard hormonal therapies. Although the etiopathogenetic mechanisms of many gynecological diseases, such as endometriosis [1] and uterine fibroids [2] are still not clear, the role of steroid hormones is undoubted. Indeed, there is an important hormonal imbalance, for example, in endometriosis [3], uterine leiomyomas [4], ovarian cancer [5], and breast cancer [6].
The father of medicine, Hippocrates, proclaimed “Let food be the medicine and medicine be the food” around 25 centuries ago. In recent studies, there is a high interest in dietary phytochemicals. Phytochemicals are chemical compounds of natural origin that can be used as therapeutic or preventive agents.
Nutraceutical compounds can exert their effects on health in different ways, including through hormonal activity. Their mechanism of action is: 1. Competition with the hormone for binding to the corresponding receptor, thanks to a structural similarity; 2. Influence on the activity of key enzymes of the biosynthetic pathway, such as in the case of isoflavones, which are moderate aromatase inhibitors, thus reducing estrogen synthesis; 3. Influence on the epigenome by affecting DNA methylation activity, histone modification, and microRNA regulation [7].
Phytoestrogens and phytoprogestins are phytochemical compounds of natural origin, which have estrogenic and progestagenic effects, respectively [8,9]. While phytoestrogen-based therapies have been extensively studied in the clinical setting, treatments with phytoprogestin are still in the preclinical stage, and their potential remains unexplored [8]. Therefore, we decided to review the current evidence supporting the preventive and therapeutic effects of phytoprogestins in female diseases.

2. Methods

In this narrative review, we performed a bibliographic search of studies evaluating the effects of dietary phytoprogestins on reproductive cells and tissues and the possible association of these nutritional compounds with gynecological diseases. The search was carried out on Pubmed using combinations of the following terms: phytochemicals [MeSH], flavonoids [MeSH], kaempferol, apigenin, naringenin, luteolin, women, uterine fibroids, endometriosis, ovarian cancer, and breast cancer. The search was narrowed to studies in humans or relevant animal models of human diseases and complemented by screening the reference lists of the selected articles. We also briefly review the pharmacological mechanisms of progesterone receptor activation and progesterone-based therapies in order to provide a background to the discussion of phytoprogestins.

3. Progesterone

Progesterone is a sex steroid hormone essential in female reproduction, including the menstrual cycle and the establishment and maintenance of pregnancy [10]. The etymology of the name derives from the Latin “pro gestationem” [11], as it allows the endometrium to pass from the proliferative to the secretory stage, facilitating the nesting of the blastocyst and is essential for maintaining pregnancy; in fact, it promotes the uterine growth and suppresses the contractility of the muscular tissue of the uterus (myometrium). In the mammary gland, it promotes the development of the gland for the secretion of milk. In addition, progesterone plays an essential role in the physiology of non-reproductive tissues, such as the cardiovascular system, the central nervous system, and bone tissue. In the brain, progesterone is neuroprotective, and its metabolite allopregnanolone is a GABAergic agonist [12,13] (Figure 1).
Steroids are ancestral molecules [11] characterized by a common base structure of cyclopentane–perhydro–phenanthrene, a polycyclic complex of 17 carbon atoms making a four-ring system. Based on the number of carbon atoms, sex steroids can be categorized into three groups: progesterone and progestins, with 21 carbon atoms, androgens, which have 19 carbon atoms, and finally estrogens, with 18 carbon atoms.
The biosynthesis of steroid hormones is the same in all organs where they are produced, such as the ovary, testis, adrenal cortex, brain, and placenta. The gonadal progesterone is mainly transported by blood to reach the target cells, while the progesterone produced by adrenal gland is mostly locally converted into glucocorticoids and androgens [14]. Progesterone circulates in the bloodstream bound to cortisol-binding globulin (approximately 10%) and serum albumin and has a relatively short half-life of only five minutes. The metabolites mainly produced in the liver are sulfates and glucuronides, which are excreted in the urine. Circulating progesterone is converted by the kidney into a mineralocorticoid, deoxycorticosterone (DOC). During the luteal phase, pregnancy, and administration of exogenous progesterone, most circulating DOC arises from this pathway and may bring unbearable side effects [14].
Progesterone exerts its physiological effect by binding to target cells via specific nuclear progesterone receptors (PR) or by binding to membrane receptors (progesterone receptor membrane component, PGRMC, or mPR). The binding with the nuclear receptors gives rise to a genomic pathway that requires a much longer response than the non-genomic one, which is triggered when progesterone binds to membrane receptors.
PRs are expressed in the human ovary [15], uterus [16], testis [17], brain [18], pancreas [19], bone tissue [20], mammary gland [21] and urinary tract [22]. PRs, together with the receptors for estradiol, mineralocorticoids, glucocorticoids, and androgens, belong to the superfamily of nuclear receptors. The nuclear progesterone receptor consists of a central binding domain for DNA (DBD) and a carboxylic terminal binding domain for the ligand (LBD). In addition, the receptor has transcription activation function (TAF) domains that interact with coactivators and corepressors to regulate the downstream target genes [23] (Figure 2). The newly transcribed progesterone receptor is assembled into an inactive multiprotein chaperone complex in the cytoplasm [24]. The receptor at this level must be inactive [25] since its activation occurs only in the presence of a link with the hormone, which induces a conformational change of the receptor [26].
Two isoforms of PR are transcribed from a single gene by alternative splicing from two distinct promoters [27,28], giving rise to transcripts that encode, respectively, for the protein isoforms A (PRA) and B (PRB) (Figure 2). PRA and PRB are identical in sequence, except that PRA lacks 164 amino acids at the N-terminal, making it the shorter of the two proteins [28].
Progesterone may act through a genomic (slow process) or a non-genomic (fast process) pathway. The classical pathways of progesterone actions are mediated via nuclear receptors. Progesterone enters the cell and binds PRs, inducing their conformational change and dimerization. The complex of progesterone with PR translocates to the nucleus and interacts with DNA-binding elements in the genome, activating the transcription of progesterone-responsive genes (Figure 2). The non-genomic (also called non-classical or extranuclear) progesterone action initiates at the cell surface with the activation of the cytoplasmic PRs or membrane-bound PRs (mPRs) and determines an intracellular signaling that elicits a rapid response [29]. These proteins include the progesterone receptor membrane component 1 (PGRMC1), its counterpart PGRMC2, and the family of membrane progesterone receptors (mPR), also known as PAQR (progestin and adipoQ) receptors [30].
Studies in mice have shown that the elimination of the PRB isoform resulted in the unhealthy development of the mammary gland [31], while the elimination of PRA caused an abnormal development of the uterus and impaired its reproductive function [32]. Therefore, in animals, a dominant expression of one of the two isoforms seems to be necessary for the normal functioning and development of some organs. On the other hand, in humans, all healthy tissues, including those of the mammary gland and uterus, have epithelial cells that express PR with the co-expression of both the PRA and PRB isoforms [33,34]. This condition suggests that the colocalization and thus the cooperative activity of PRA and PRB mediate the action of PR in humans. Although the two isoforms are expressed in the same way in most human tissues, there is a different expression in the endometrium. In fact, during the secretory phase of the menstrual cycle, when there are high levels of circulating progesterone, the PRA isoform is poorly expressed, resulting in a clear predominance of PRB [33].
In breast and endometrial cancers, there are substantial differences in progesterone levels and its isoforms compared to normal tissues. In fact, in healthy tissues deriving from the mammary gland, epithelial cells equally express both PR isoforms [34], while in neoplastic biopsies, it is possible to see a significant increase in the expression, alternatively, of PRA or PRB [34,35]. Similarly, in endometrial cancer, it is common to find only one of the two isoforms expressed, either PRA or PRB, suggesting that the lack of co-expression of both isoforms is an early event of the onset of endometrial cancer [36].
A third isoform (PRC) has been identified in the human placenta [37]. PRC is an isoform with a truncated N-terminal domain, with a molecular mass of approximately 60 kDa, present in the cytoplasm. PRC lacks the first zinc finger of the DBD, but it can still bind progesterone. The actions of PRC are not clear, but it can form heterodimers with PRA and PRB and, in this way, regulate the transcriptional activity of the PR isoforms [37,38].

4. Progesterone-Based Drug Therapy

Progestogens are the most common compounds used as drug therapy for the treatment of women’s diseases. Many gynecological diseases are treated with synthetic progestin-based drugs. In the United States, endometrial cancer is one of the most common gynecological cancers, with 46,470 new cases and 8,120 deaths in 2011 [39]. Even if the molecular mechanisms involved in endometrial carcinogenesis are not clear, it seems that chronic exposure to estrogen and its metabolites without sufficient counterbalance of progesterone has proliferative effects [40,41] and is harmful to DNA [42,43]. Based on the antiestrogenic role of progesterone, many patients affected by endometrial cancer may have an indication to progesterone-based therapy, particularly in case of contraindications to surgery or desire for fertility maintenance. Indeed, women with endometrial hyperplasia and well-differentiated endometrial adenocarcinoma show a good response to progestogen therapy [44]. However, as the severity of the disease increases, the efficacy of progestogens decreases [45].
Other estrogen-dependent female pathologies with a high social impact, such as endometriosis, are often treated with progestin therapies [46,47], including synthetic progestins such as medroxyprogesterone acetate or dienogest [48,49]. Uterine fibroids may also be treated with progestins. Since the first reports of decades ago [50], studies have focused on the effects of different progestins on uterine fibroids, with different drug dosages and regimens. For example, medroxyprogesterone acetate [51] and dienogest [52,53] have shown a regressive effect on uterine fibroids.
Moreover, progestogens are widely used as a contraceptive method and in menopausal hormone therapy, in combination with estrogens. These therapies may also have an effect of prevention of ovarian cancer, but they increase the risk of venous thromboembolism and present side effects [54,55]. Therefore, the identification of alternative progestogens is clinically significant. Numerous studies in the literature indicate a great interest in developing phytoprogestogens, such as botanical extracts or food supplements, hoping to provide the beneficial effects of progestins while avoiding the side effects.
Selective progesterone receptor modulator (SPRM) is a class of synthetic ligands that act on the PR and tend to be more tissue-specific than progestins. The mechanism of action of SPRMs occurs through binding to PR, resulting in a conformational change of the receptor. The action can be agonistic, antagonistic, or mixed. The agonist action of SPRMs involves the recruitment of different coactivators to induce transcriptional activity and occurs in tissues where high levels of coactivators are present, while antagonist activity occurs where corepressors are in excess (Figure 2).
When the PR is inactive, SPRMs bind to the receptor and activate it. The binding involves nuclear import, which gives the receptor the property of dimerization. In the nucleus, the dimer interacts with the response element in the DNA, causing the up-regulation or down-regulation of the gene [56,57]. The action of SPRMs also depends on the ratio of PR-A and PR-B in the tissue and on the specific binding affinity of the SPRMs for each receptor isoform [58]. SPRMs have been developed for clinical applications, considering their tissue selectivity and low rate of side effects [59]. Their application is principally for the treatment of uterine fibroids [60], endometriosis [61], and breast cancer [62].
Despite having beneficial effects, for example, in the treatment of uterine fibroids, the prolonged use of SPRMs may lead to endometrial hyperplasia and other side effects. Indeed, it has been shown that long-term use of the SPRM asoprisnil results in long-term damage to the endometrium. Ulipristal acetate has been approved in Canada and Europe as a presurgical therapy for patients with uterine fibroids to control bleeding, and in the United States for emergency contraception. However, it has raised concerns due to liver toxicity [63], as well as telapristone acetate, which was stopped in 2009. Vilaprisan is still under study, and its possible collateral effects are not yet known [64].

5. Phytoprogestins

Phytoprogestins are chemical compounds of vegetal origin that have progesterone-like activity and can function as non-steroidal SPRMs. Unlike estrogenic counterparts, which have been extensively studied, the literature reports much fewer studies on phytoprogestins. The following phytoprogestins have been identified: kaempferol, apigenin, luteolin, and naringenin (Figure 3).

5.1. Kaempferol

Kaempferol (KP: 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a flavonoid found in several botanical families, including Pteridophyta, Pinophyta, and Magnoliophyta (Figure 3). Flavonoids are a group of secondary metabolites widespread in nature. These substances are known for the benefits of their consumption, which seems to reduce the risk of cancer and cardiovascular diseases [65]. A case–control study showed a 40% reduction (adjusted odds ratio 0.60) in breast cancer risk in Chinese women in the upper quartile of serum KP levels [66]. The risk of epithelial ovarian cancer was also decreased by 40% among women in the highest quintile of KP dietary intake of a large prospective cohort in the USA, the Nurses’ Health Study [67]. Several studies have shown that KP has excellent antioxidant properties. In fact, it is able to decrease, even at low concentrations, the levels of the hydroxyl radical and peroxynitrite, highly reactive species capable of causing severe damage to DNA, proteins, and lipids [68]. In addition, KP has anti-inflammatory properties not only in vitro but also in vivo [69,70].
KP inhibits estrogen receptor-α, causing antiestrogenic effects, depending on the concentration of endogenous estrogens. The antiestrogenic activity of KP results in the inhibition of the growth of hormone-dependent tumors; this activity has been demonstrated in numerous in vitro studies, for example, in endometrial carcinoma cells [71] and two lines of breast cancer cells [72].
In uterine fibroids, despite being hormone-dependent tumors with severe symptoms, the effects of KP have not been extensively studied. KP treatment reduces the expression of the estrogen receptor, thus inhibiting the cell proliferation of human uterine leiomyoma cells in vitro [73], although its therapeutic effect in vivo remains unknown (Table 1).

5.2. Apigenin and Luteolin

Apigenin (4’,5,7-trihydroxyflavone) is found in a wide range of plants, including chamomile (Matricaria recutita). The traditional use of chamomile as a treatment for insomnia and anxiety has led to investigations of its active constituents, including apigenin. Apigenin is mainly present as a glycosylated compound in significant quantities in vegetables (parsley, celery, onions), fruit (oranges), herbs (chamomile, thyme, oregano, basil), and vegetable drinks (tea, beer, and wine) [80]. Apigenin is considered a phytoestrogen, although it has a much lower potency than other phytoestrogens such as genistein [81]. However, in recent studies, it has emerged that apigenin is also a phytoprogestin. A study found that apigenin reduces the risk of breast tumors in women exposed to prolonged treatment with medroxyprogesterone acetate [82,83]. A study by Horwitz and Sartorius showed that prolonged progestogen therapy could lead to the development of breast cancer through the activation of stem cells that differentiate into cancer cells [84]. In animals subjected to medroxyprogesterone therapy, apigenin administration decreased the incidence of tumors by 50% [82].
Apigenin has an antitumor effect by acting through a variety of mechanisms, including the induction of cell cycle arrest and apoptosis [74], attenuation of phosphorylation of MAP kinase [85] and inhibition of the proinflammatory cytokine interleukin-6 [86]. In vitro studies have shown that treating human breast cancer cell lines [75] with apigenin significantly reduced the expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 [87]. The significant reduction in VEGF disadvantages the tumor growth and development in breast tissue.
Apigenin taken orally is detectable in peripheral blood at concentrations sufficient to be biologically effective [88]. Immediately after ingestion, its concentration increases, and it remains in circulation for a long time, suggesting that it can accumulate within tissues to levels sufficient to exert chemo-preventive effects [89]. Furthermore, apigenin increased the endometrial expression of Hand2, which is a transcription factor stimulated by progesterone. The activation of Hand2 by progesterone allows an antiproliferative action in the endometrium, further suggesting that apigenin is a phytoprogestin. Apigenin appears to be non-toxic even at high doses, as suggested by a study in which it was repeatedly administered to animals up to 50 mg/kg per 10–13 days, and no signs of toxicity were observed. Apigenin seems to reduce endometrial (Ishikawa) cell proliferation regardless of progesterone [90]. In vivo, apigenin is rapidly metabolized to luteolin.
Luteolin, a flavonoid found in more than 300 plant species, many of which are readily available in the human diet, has been demonstrated to be an excellent progesterone antagonist [91] (Figure 3). A study showed that luteolin effectively inhibits the growth of progestogen-dependent human xenograft tumors, inhibiting angiogenesis and limiting the conversion of breast cancer cells to stem cell-like cells [76,77]. Interestingly, preliminary results suggest that luteolin may inhibit the growth of endometriotic lesions in a mouse model [92].

5.3. Naringenin

Naringenin (4,5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen- 4-one) belongs to the subclass of flavanones (Figure 3). It is a colorless compound that gives the typical bitter taste in citrus, including grapefruit, orange, and lemon [93].
Naringenin has antioxidant, immunomodulatory, anti-inflammatory, nephroprotective, hepatoprotective, neuroprotective, antidiabetic, antitumor, and anti-atherosclerotic properties. In addition, naringenin has a high bioavailability [94,95].
Naringenin is able to inhibit the recruitment and generation of reactive oxygen species (ROS), thereby reducing oxidative stress [78,96]. Moreover, it acts directly on the NF-KB pathway in vitro and in vivo [97]. This signaling pathway is known to be activated by external agents such as pathogens. In the presence of external agents, pro-inflammatory cytokines such as IL-1 and TNF-α are recalled [98]. This stimulation and this recall involve the activation of the IKB kinase complex (IKK), which eventually phosphorylates IKK β. The phosphorylated IKB allows NF-KB to translocate into the nucleus, causing inflammatory responses [99]. Naringenin can prevent the degradation of IKB, inhibiting the transcription activity of NF-KB [98].
In numerous studies, it has emerged that naringenin is also an excellent anti-fibrotic agent [79]. In fact, naringenin was able to decrease the expression of collagen, fibronectin, and Smad3 induced by TGF-β and to inhibit Plasminogen Activator-1 (PAI-1) in hepatic cells [100]. Some of these mechanisms are similar to those fueled by progesterone in uterine fibroids [4].
In a study by Rosenberg et al. [101] it emerged that naringenin may also have progestin-like activity. More specifically, the study showed that the progestin activity of naringenin is weak and acts at concentrations around 10−5–10−6 M. These concentration levels are similar to those deemed necessary for the action of resveratrol as a weak estrogen [102], but not for the activity of synthetic progestins such as norgestrel and norgestimate. In fact, the biological activity of naringenin compared to norgestimate is about 104-fold lower.
The effects that naringenin as a phytoprogestin could have on diseases such as endometriosis and uterine fibroids remain to be investigated. An in vitro study found that naringenin induced apoptosis and inhibited the proliferation of immortalized cell lines derived from the endocervical epithelium of a premenopausal woman undergoing hysterectomy for endometriosis [103].

6. Conclusions

There is large unexplored potential in using plant-derived substances to treat human diseases. Some of these phytochemicals have been characterized as phytoprogestins, based on their similarity with progesterone and their pharmacological interaction with PR, functioning as agonists, partial agonists, or antagonists. At least four phytoprogestins have been studied in vitro with promising results such as the antitumoral effects of KP, apigenin, and luteolin, and the anti-fibrotic effects of naringenin. Although there are limited data in the literature, it appears that phytoprogestins could be a good tool for preventing and treating hormone-dependent diseases such as endometriosis, uterine fibroids, ovarian cancer, and breast cancer, with potential reduction in the side effects of currently available hormone treatments. The next step is to proceed with tests in well-characterized animal models to define the therapeutic mechanisms and safety of these substances, along with observational human studies correlating the dietary ingestion of phytoprogestins with the prevalence and incidence of gynecologic diseases.

Author Contributions

Writing, S.G., P.P., A.Z., G.D.C., A.C., F.M.R., P.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bulletti, C.; Coccia, M.E.; Battistoni, S.; Borini, A. Endometriosis and infertility. J. Assist. Reprod. Genet. 2010, 27, 441–447. [Google Scholar] [CrossRef]
  2. Islam, M.S.; Greco, S.; Janjusevic, M.; Ciavattini, A.; Giannubilo, S.R.; D’Adderio, A.; Biagini, A.; Fiorini, R.; Castellucci, M.; Ciarmela, P. Growth factors and pathogenesis. Best Pract. Res. Clin. Obstet. Gynaecol. 2016, 34, 25–36. [Google Scholar] [CrossRef]
  3. Marquardt, R.M.; Kim, T.H.; Shin, J.H.; Jeong, J.W. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? Int. J. Mol. Sci. 2019, 20, 3822. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Reis, F.M.; Bloise, E.; Ortiga-Carvalho, T.M. Hormones and pathogenesis of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2016, 34, 13–24. [Google Scholar] [CrossRef] [PubMed]
  5. Momenimovahed, Z.; Tiznobaik, A.; Taheri, S.; Salehiniya, H. Ovarian cancer in the world: Epidemiology and risk factors. Int. J. Womens Health 2019, 11, 287–299. [Google Scholar] [CrossRef] [Green Version]
  6. Group, E.C.W. Hormones and breast cancer. Hum. Reprod. Update 2004, 10, 281–293. [Google Scholar] [CrossRef] [PubMed]
  7. Dietz, B.M.; Hajirahimkhan, A.; Dunlap, T.L.; Bolton, J.L. Botanicals and Their Bioactive Phytochemicals for Women’s Health. Pharmacol. Rev. 2016, 68, 1026–1073. [Google Scholar] [CrossRef]
  8. Hajirahimkhan, A.; Dietz, B.M.; Bolton, J.L. Botanical modulation of menopausal symptoms: Mechanisms of action? Planta Med. 2013, 79, 538–553. [Google Scholar] [CrossRef] [Green Version]
  9. Zava, D.T.; Dollbaum, C.M.; Blen, M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc. Soc. Exp. Biol. Med. 1998, 217, 369–378. [Google Scholar] [CrossRef]
  10. Scarpin, K.M.; Graham, J.D.; Mote, P.A.; Clarke, C.L. Progesterone action in human tissues: Regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl. Recept. Signal 2009, 7, e009. [Google Scholar] [CrossRef] [Green Version]
  11. Taraborrelli, S. Physiology, production and action of progesterone. Acta Obstet. Gynecol. Scand. 2015, 94, 8–16. [Google Scholar] [CrossRef] [PubMed]
  12. Guennoun, R. Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant. Int. J. Mol. Sci. 2020, 21, 5271. [Google Scholar] [CrossRef] [PubMed]
  13. Piette, P.C.M. The pharmacodynamics and safety of progesterone. Best Pract. Res. Clin. Obstet. Gynaecol. 2020, 69, 13–29. [Google Scholar] [CrossRef]
  14. Amadori, A.; Cavallari, C.; Giacomucci, E.; Macrelli, S.; Mastronuzzi, G.; Ucci, N. Fisiologia Della Riproduzione; CLUEB: Bologna, Italy, 1994; pp. 1–92. [Google Scholar]
  15. Horie, K.; Takakura, K.; Fujiwara, H.; Suginami, H.; Liao, S.; Mori, T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Hum. Reprod. 1992, 7, 184–190. [Google Scholar] [CrossRef] [PubMed]
  16. Thijssen, J.H. Progesterone receptors in the human uterus and their possible role in parturition. J. Steroid Biochem. Mol. Biol. 2005, 97, 397–400. [Google Scholar] [CrossRef] [PubMed]
  17. Abid, S.; Gokral, J.; Maitra, A.; Meherji, P.; Kadam, S.; Pires, E.; Modi, D. Altered expression of progesterone receptors in testis of infertile men. Reprod. Biomed. Online 2008, 17, 175–184. [Google Scholar] [CrossRef]
  18. Brinton, R.D.; Thompson, R.F.; Foy, M.R.; Baudry, M.; Wang, J.; Finch, C.E.; Morgan, T.E.; Pike, C.J.; Mack, W.J.; Stanczyk, F.Z.; et al. Progesterone receptors: Form and function in brain. Front. Neuroendocrinol. 2008, 29, 313–339. [Google Scholar] [CrossRef] [Green Version]
  19. Doglioni, C.; Gambacorta, M.; Zamboni, G.; Coggi, G.; Viale, G. Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. Am. J. Pathol. 1990, 137, 999–1005. [Google Scholar]
  20. Bland, R. Steroid hormone receptor expression and action in bone. Clin. Sci. 2000, 98, 217–240. [Google Scholar] [CrossRef]
  21. Branchini, G.; Schneider, L.; Cericatto, R.; Capp, E.; Brum, I.S. Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas. Endocrine 2009, 35, 459–466. [Google Scholar] [CrossRef]
  22. Batra, S.C.; Iosif, C.S. Progesterone receptors in the female lower urinary tract. J. Urol. 1987, 138, 1301–1304. [Google Scholar] [CrossRef]
  23. Lonard, D.M.; Lanz, R.B.; O'Malley, B.W. Nuclear receptor coregulators and human disease. Endocr. Rev. 2007, 28, 575–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Smith, D.F.; Faber, L.E.; Toft, D.O. Purification of unactivated progesterone receptor and identification of novel receptor-associated proteins. J. Biol. Chem. 1990, 265, 3996–4003. [Google Scholar] [CrossRef]
  25. Pratt, W.B.; Galigniana, M.D.; Morishima, Y.; Murphy, P.J. Role of molecular chaperones in steroid receptor action. Essays Biochem. 2004, 40, 41–58. [Google Scholar] [CrossRef] [PubMed]
  26. Tata, J.R. Signalling through nuclear receptors. Nat. Rev. Mol. Cell Biol. 2002, 3, 702–710. [Google Scholar] [CrossRef] [PubMed]
  27. Gronemeyer, H.; Meyer, M.E.; Bocquel, M.T.; Kastner, P.; Turcotte, B.; Chambon, P. Progestin receptors: Isoforms and antihormone action. J. Steroid. Biochem. Mol. Biol. 1991, 40, 271–278. [Google Scholar] [CrossRef]
  28. Kastner, P.; Krust, A.; Turcotte, B.; Stropp, U.; Tora, L.; Gronemeyer, H.; Chambon, P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990, 9, 1603–1614. [Google Scholar] [CrossRef]
  29. Losel, R.M.; Besong, D.; Peluso, J.J.; Wehling, M. Progesterone receptor membrane component 1--many tasks for a versatile protein. Steroids 2008, 73, 929–934. [Google Scholar] [CrossRef]
  30. Kowalik, M.K.; Rekawiecki, R.; Kotwica, J. The putative roles of nuclear and membrane-bound progesterone receptors in the female reproductive tract. Reprod. Biol. 2013, 13, 279–289. [Google Scholar] [CrossRef] [PubMed]
  31. Mulac-Jericevic, B.; Lydon, J.P.; DeMayo, F.J.; Conneely, O.M. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Natl. Acad. Sci. USA 2003, 100, 9744–9749. [Google Scholar] [CrossRef] [Green Version]
  32. Mulac-Jericevic, B.; Mullinax, R.A.; De Mayo, F.J.; Lydon, J.P.; Conneely, O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000, 289, 1751–1754. [Google Scholar] [CrossRef] [PubMed]
  33. Mote, P.A.; Balleine, R.L.; McGowan, E.M.; Clarke, C.L. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 1999, 84, 2963–2971. [Google Scholar] [CrossRef] [PubMed]
  34. Mote, P.A.; Bartow, S.; Tran, N.; Clarke, C.L. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat. 2002, 72, 163–172. [Google Scholar] [CrossRef]
  35. Graham, J.D.; Yeates, C.; Balleine, R.L.; Harvey, S.S.; Milliken, J.S.; Bilous, A.M.; Clarke, C.L. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 1995, 55, 5063–5068. [Google Scholar] [PubMed]
  36. Arnett-Mansfield, R.L.; deFazio, A.; Wain, G.V.; Jaworski, R.C.; Byth, K.; Mote, P.A.; Clarke, C.L. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001, 61, 4576–4582. [Google Scholar]
  37. Taylor, A.H.; McParland, P.C.; Taylor, D.J.; Bell, S.C. The cytoplasmic 60 kDa progesterone receptor isoform predominates in the human amniochorion and placenta at term. Reprod. Biol. Endocrinol. 2009, 7, 22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Wei, L.L.; Hawkins, P.; Baker, C.; Norris, B.; Sheridan, P.L.; Quinn, P.G. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity. Mol. Endocrinol. 1996, 10, 1379–1387. [Google Scholar] [CrossRef] [Green Version]
  39. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212–236. [Google Scholar] [CrossRef]
  40. Key, T.J.; Pike, M.C. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer 1988, 57, 205–212. [Google Scholar] [CrossRef] [Green Version]
  41. Siiteri, P.K. Steroid hormones and endometrial cancer. Cancer Res. 1978, 38, 4360–4366. [Google Scholar]
  42. Doherty, J.A.; Weiss, N.S.; Fish, S.; Fan, W.; Loomis, M.M.; Sakoda, L.C.; Rossing, M.A.; Zhao, L.P.; Chen, C. Polymorphisms in nucleotide excision repair genes and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 1873–1882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Shibutani, S.; Ravindernath, A.; Suzuki, N.; Terashima, I.; Sugarman, S.M.; Grollman, A.P.; Pearl, M.L. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000, 21, 1461–1467. [Google Scholar] [CrossRef]
  44. Gompel, A. Progesterone and endometrial cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2020, 69, 95–107. [Google Scholar] [CrossRef] [PubMed]
  45. Ethier, J.L.; Desautels, D.N.; Amir, E.; MacKay, H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol. Oncol. 2017, 147, 158–166. [Google Scholar] [CrossRef] [PubMed]
  46. Vierikko, P.; Kauppila, A.; Ronnberg, L.; Vihko, R. Steroidal regulation of endometriosis tissue: Lack of induction of 17 beta-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol. Fertil. Steril. 1985, 43, 218–224. [Google Scholar] [CrossRef]
  47. Brandon, D.D.; Erickson, T.E.; Keenan, E.J.; Strawn, E.Y.; Novy, M.J.; Burry, K.A.; Warner, C.; Clinton, G.M. Estrogen receptor gene expression in human uterine leiomyomata. J. Clin. Endocrinol. Metab. 1995, 80, 1876–1881. [Google Scholar] [CrossRef]
  48. Soper, J.T.; McCarty, K.S., Jr.; Creasman, W.T.; Clarke-Pearson, D.L. Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am. J. Obstet. Gynecol. 1984, 150, 437–439. [Google Scholar] [CrossRef]
  49. Murji, A.; Biberoglu, K.; Leng, J.; Mueller, M.D.; Romer, T.; Vignali, M.; Yarmolinskaya, M. Use of dienogest in endometriosis: A narrative literature review and expert commentary. Curr. Med. Res. Opin. 2020, 36, 895–907. [Google Scholar] [CrossRef] [Green Version]
  50. Goodman, A.L. Progesterone therapy in uterine fibromyoma. J. Clin. Endocrinol. Metab. 1946, 6, 402–408. [Google Scholar] [CrossRef]
  51. Lumbiganon, P.; Rugpao, S.; Phandhu-fung, S.; Laopaiboon, M.; Vudhikamraksa, N.; Werawatakul, Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: A multicentre case-control study. BJOG Int. J. Obstet. Gynaecol. 1996, 103, 909–914. [Google Scholar] [CrossRef]
  52. Schindler, A.E.; Campagnoli, C.; Druckmann, R.; Huber, J.; Pasqualini, J.R.; Schweppe, K.W.; Thijssen, J.H. Classification and pharmacology of progestins. Maturitas 2008, 61, 171–180. [Google Scholar] [CrossRef] [PubMed]
  53. Ichigo, S.; Takagi, H.; Matsunami, K.; Suzuki, N.; Imai, A. Beneficial effects of dienogest on uterine myoma volume: A retrospective controlled study comparing with gonadotropin-releasing hormone agonist. Arch. Gynecol. Obstet. 2011, 284, 667–670. [Google Scholar] [CrossRef] [PubMed]
  54. Rott, H. Thrombotic risks of oral contraceptives. Curr. Opin. Obstet. Gynecol. 2012, 24, 235–240. [Google Scholar] [CrossRef] [PubMed]
  55. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: A guideline. Fertil. Steril. 2017, 107, 43–51. [Google Scholar] [CrossRef] [Green Version]
  56. DeMarzo, A.M.; Beck, C.A.; Onate, S.A.; Edwards, D.P. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. Proc. Natl. Acad. Sci. USA 1991, 88, 72–76. [Google Scholar] [CrossRef] [Green Version]
  57. Smith, C.L.; O'Malley, B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 2004, 25, 45–71. [Google Scholar] [CrossRef]
  58. Bouchard, P.; Chabbert-Buffet, N.; Fauser, B.C. Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety. Fertil. Steril. 2011, 96, 1175–1189. [Google Scholar] [CrossRef]
  59. Wilkens, J.; Male, V.; Ghazal, P.; Forster, T.; Gibson, D.A.; Williams, A.R.; Brito-Mutunayagam, S.L.; Craigon, M.; Lourenco, P.; Cameron, I.T.; et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. J. Immunol. 2013, 191, 2226–2235. [Google Scholar] [CrossRef]
  60. Donnez, J. Uterine Fibroids and Progestogen Treatment: Lack of Evidence of Its Efficacy: A Review. J. Clin. Med. 2020, 9, 3948. [Google Scholar] [CrossRef]
  61. Bressler, L.H.; Bernardi, L.A.; Snyder, M.A.; Wei, J.J.; Bulun, S. Treatment of endometriosis-related chronic pelvic pain with Ulipristal Acetate and associated endometrial changes. HSOA J. Reprod. Med. Gynaecol. Obstet. 2017, 2. [Google Scholar] [CrossRef] [Green Version]
  62. Lee, O.; Sullivan, M.E.; Xu, Y.; Rogers, C.; Muzzio, M.; Helenowski, I.; Shidfar, A.; Zeng, Z.; Singhal, H.; Jovanovic, B.; et al. Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate. Clin. Cancer Res. 2020, 26, 25–34. [Google Scholar] [CrossRef] [Green Version]
  63. Dinis-Oliveira, R.J. Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: Insights into the mechanisms implicated in the hepatic toxicity. Drug Metab. Rev. 2021, 1–9. [Google Scholar] [CrossRef]
  64. Islam, M.S.; Afrin, S.; Jones, S.I.; Segars, J. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility. Endocr. Rev. 2020, 41, 643–694. [Google Scholar] [CrossRef]
  65. Middleton, E., Jr.; Kandaswami, C.; Theoharides, T.C. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673–751. [Google Scholar] [PubMed]
  66. Feng, X.L.; Zhan, X.X.; Zuo, L.S.; Mo, X.F.; Zhang, X.; Liu, K.Y.; Li, L.; Zhang, C.X. Associations between serum concentration of flavonoids and breast cancer risk among Chinese women. Eur. J. Nutr. 2021, 60, 1347–1362. [Google Scholar] [CrossRef] [PubMed]
  67. Gates, M.A.; Tworoger, S.S.; Hecht, J.L.; De Vivo, I.; Rosner, B.; Hankinson, S.E. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int. J. Cancer 2007, 121, 2225–2232. [Google Scholar] [CrossRef] [PubMed]
  68. Wang, L.; Tu, Y.C.; Lian, T.W.; Hung, J.T.; Yen, J.H.; Wu, M.J. Distinctive antioxidant and antiinflammatory effects of flavonols. J. Agric. Food Chem. 2006, 54, 9798–9804. [Google Scholar] [CrossRef] [PubMed]
  69. Orhan, I.; Kupeli, E.; Terzioglu, S.; Yesilada, E. Bioassay-guided isolation of kaempferol-3-O-beta-D-galactoside with anti-inflammatory and antinociceptive activity from the aerial part of Calluna vulgaris L. J. Ethnopharmacol. 2007, 114, 32–37. [Google Scholar] [CrossRef]
  70. Park, M.J.; Lee, E.K.; Heo, H.S.; Kim, M.S.; Sung, B.; Kim, M.K.; Lee, J.; Kim, N.D.; Anton, S.; Choi, J.S.; et al. The anti-inflammatory effect of kaempferol in aged kidney tissues: The involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinase pathways. J. Med. Food 2009, 12, 351–358. [Google Scholar] [CrossRef]
  71. Chuwa, A.H.; Sone, K.; Oda, K.; Tanikawa, M.; Kukita, A.; Kojima, M.; Oki, S.; Fukuda, T.; Takeuchi, M.; Miyasaka, A.; et al. Kaempferol, a natural dietary flavonoid, suppresses 17beta-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer. Oncol. Lett. 2018, 16, 6195–6201. [Google Scholar] [CrossRef] [Green Version]
  72. Hu, G.; Liu, H.; Wang, M.; Peng, W. IQ Motif Containing GTPase-Activating Protein 3 (IQGAP3) Inhibits Kaempferol-Induced Apoptosis in Breast Cancer Cells by Extracellular Signal-Regulated Kinases 1/2 (ERK1/2) Signaling Activation. Med. Sci. Monit. 2019, 25, 7666–7674. [Google Scholar] [CrossRef]
  73. Li, Y.; Ding, Z.; Wu, C. Mechanistic Study of the Inhibitory Effect of Kaempferol on Uterine Fibroids In Vitro. Med. Sci. Monit. 2016, 22, 4803–4808. [Google Scholar] [CrossRef] [Green Version]
  74. Horinaka, M.; Yoshida, T.; Shiraishi, T.; Nakata, S.; Wakada, M.; Sakai, T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 2006, 5, 945–951. [Google Scholar] [CrossRef] [Green Version]
  75. Mafuvadze, B.; Benakanakere, I.; Hyder, S.M. Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause 2010, 17, 1055–1063. [Google Scholar] [CrossRef] [PubMed]
  76. Cook, M.T.; Liang, Y.; Besch-Williford, C.; Goyette, S.; Mafuvadze, B.; Hyder, S.M. Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts. Springerplus 2015, 4, 444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Cook, M.T.; Liang, Y.; Besch-Williford, C.; Hyder, S.M. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer 2017, 9, 9–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Manchope, M.F.; Calixto-Campos, C.; Coelho-Silva, L.; Zarpelon, A.C.; Pinho-Ribeiro, F.A.; Georgetti, S.R.; Baracat, M.M.; Casagrande, R.; Verri, W.A., Jr. Naringenin Inhibits Superoxide Anion-Induced Inflammatory Pain: Role of Oxidative Stress, Cytokines, Nrf-2 and the NO-cGMP-PKG-KATP Channel Signaling Pathway. PLoS ONE 2016, 11, e0153015. [Google Scholar] [CrossRef] [PubMed]
  79. Lee, M.H.; Yoon, S.; Moon, J.O. The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats. Biol. Pharm. Bull. 2004, 27, 72–76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Hostetler, G.L.; Ralston, R.A.; Schwartz, S.J. Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity. Adv. Nutr. 2017, 8, 423–435. [Google Scholar] [CrossRef] [Green Version]
  81. Mabry, T.; Markham, K.R.; Thomas, M.B. The Systematic Identification of Flavonoids; Springer: Berlin/Heidelberg, Germany, 2012. [Google Scholar]
  82. Mafuvadze, B.; Benakanakere, I.; Lopez Perez, F.R.; Besch-Williford, C.; Ellersieck, M.R.; Hyder, S.M. Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev. Res. 2011, 4, 1316–1324. [Google Scholar] [CrossRef] [Green Version]
  83. Mafuvadze, B.; Liang, Y.; Besch-Williford, C.; Zhang, X.; Hyder, S.M. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm. Cancer 2012, 3, 160–171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Horwitz, K.B.; Sartorius, C.A. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: A hypothesis. J. Clin. Endocrinol. Metab. 2008, 93, 3295–3298. [Google Scholar] [CrossRef] [Green Version]
  85. Yin, F.; Giuliano, A.E.; Law, R.E.; Van Herle, A.J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res. 2001, 21, 413–420. [Google Scholar] [PubMed]
  86. Lee, H.H.; Jung, J.; Moon, A.; Kang, H.; Cho, H. Antitumor and Anti-Invasive Effect of Apigenin on Human Breast Carcinoma through Suppression of IL-6 Expression. Int. J. Mol. Sci. 2019, 20, 3143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Hyder, S.M. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer 2006, 13, 667–687. [Google Scholar] [CrossRef]
  88. Meyer, H.; Bolarinwa, A.; Wolfram, G.; Linseisen, J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab. 2006, 50, 167–172. [Google Scholar] [CrossRef]
  89. Chen, D.; Landis-Piwowar, K.R.; Chen, M.S.; Dou, Q.P. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res. 2007, 9, R80. [Google Scholar] [CrossRef] [Green Version]
  90. Dean, M.; Austin, J.; Jinhong, R.; Johnson, M.E.; Lantvit, D.D.; Burdette, J.E. The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus. Horm. Cancer 2018, 9, 265–277. [Google Scholar] [CrossRef]
  91. Fidelis, Q.C.; Faraone, I.; Russo, D.; Aragao Catunda, F.E., Jr.; Vignola, L.; de Carvalho, M.G.; de Tommasi, N.; Milella, L. Chemical and Biological insights of Ouratea hexasperma (A. St.-Hil.) Baill.: A source of bioactive compounds with multifunctional properties. Nat. Prod. Res. 2019, 33, 1500–1503. [Google Scholar] [CrossRef]
  92. Park, S.; Lim, W.; You, S.; Song, G. Ameliorative effects of luteolin against endometriosis progression in vitro and in vivo. J. Nutr. Biochem. 2019, 67, 161–172. [Google Scholar] [CrossRef]
  93. Zaidun, N.H.; Thent, Z.C.; Latiff, A.A. Combating oxidative stress disorders with citrus flavonoid: Naringenin. Life Sci. 2018, 208, 111–122. [Google Scholar] [CrossRef]
  94. Pereira-Caro, G.; Borges, G.; van der Hooft, J.; Clifford, M.N.; Del Rio, D.; Lean, M.E.; Roberts, S.A.; Kellerhals, M.B.; Crozier, A. Orange juice (poly)phenols are highly bioavailable in humans. Am. J. Clin. Nutr. 2014, 100, 1378–1384. [Google Scholar] [CrossRef]
  95. Kanaze, F.I.; Bounartzi, M.I.; Georgarakis, M.; Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur. J. Clin. Nutr. 2007, 61, 472–477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Martinez, R.M.; Pinho-Ribeiro, F.A.; Steffen, V.S.; Caviglione, C.V.; Vignoli, J.A.; Barbosa, D.S.; Baracat, M.M.; Georgetti, S.R.; Verri, W.A., Jr.; Casagrande, R. Naringenin Inhibits UVB Irradiation-Induced Inflammation and Oxidative Stress in the Skin of Hairless Mice. J. Nat. Prod. 2015, 78, 1647–1655. [Google Scholar] [CrossRef] [PubMed]
  97. Pinho-Ribeiro, F.A.; Zarpelon, A.C.; Fattori, V.; Manchope, M.F.; Mizokami, S.S.; Casagrande, R.; Verri, W.A., Jr. Naringenin reduces inflammatory pain in mice. Neuropharmacology 2016, 105, 508–519. [Google Scholar] [CrossRef] [PubMed]
  98. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1, a001651. [Google Scholar] [CrossRef] [Green Version]
  99. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109, S81–S96. [Google Scholar] [CrossRef] [Green Version]
  100. Liu, X.; Wang, W.; Hu, H.; Tang, N.; Zhang, C.; Liang, W.; Wang, M. Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm. Res. 2006, 23, 82–89. [Google Scholar] [CrossRef]
  101. Rosenberg, R.S.; Grass, L.; Jenkins, D.J.; Kendall, C.W.; Diamandis, E.P. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. Biochem. Biophys. Res. Commun. 1998, 248, 935–939. [Google Scholar] [CrossRef] [Green Version]
  102. Gehm, B.D.; McAndrews, J.M.; Chien, P.Y.; Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 14138–14143. [Google Scholar] [CrossRef] [Green Version]
  103. Park, S.; Lim, W.; Bazer, F.W.; Song, G. Naringenin induces mitochondria-mediated apoptosis and endoplasmic reticulum stress by regulating MAPK and AKT signal transduction pathways in endometriosis cells. Mol. Hum. Reprod. 2017, 23, 842–854. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Nutrients 13 04326 g001 550
Figure 1. Schematic representation of the organs in which progesterone performs functions. Progesterone acts in reproductive as well as in non-reproductive tissues. NOS = nitric oxide synthase, NO = nitric oxide.
Figure 1. Schematic representation of the organs in which progesterone performs functions. Progesterone acts in reproductive as well as in non-reproductive tissues. NOS = nitric oxide synthase, NO = nitric oxide.
Nutrients 13 04326 g001
Nutrients 13 04326 g002 550
Figure 2. Progesterone receptors and their activation. The nuclear receptor is formed by two promoter regions on the PR gene, one for PRA and one for PRB, and these two promoters allow the synthesis of the two separate mRNA transcripts that code for the two different isoforms PRA and PRB. DBD = DNA-binding domain, H = hinge, LBD = ligand-binding domain, SPRM = selective progesterone receptor modulator, PRE = progesterone responsive element, TF = transcription factor.
Figure 2. Progesterone receptors and their activation. The nuclear receptor is formed by two promoter regions on the PR gene, one for PRA and one for PRB, and these two promoters allow the synthesis of the two separate mRNA transcripts that code for the two different isoforms PRA and PRB. DBD = DNA-binding domain, H = hinge, LBD = ligand-binding domain, SPRM = selective progesterone receptor modulator, PRE = progesterone responsive element, TF = transcription factor.
Nutrients 13 04326 g002
Nutrients 13 04326 g003 550
Figure 3. Chemical structure of phytoprogestins.
Figure 3. Chemical structure of phytoprogestins.
Nutrients 13 04326 g003
Table
Table 1. Effects of phytoprogestins that suggest their potential to treat women’s diseases.
Table 1. Effects of phytoprogestins that suggest their potential to treat women’s diseases.
SubstanceStudy DesignEffectsSignificanceReferences
KaempferolExperiments in mice and ratsAnti-inflammatoryCould be useful to treat chronic pelvic pain and its causes[69,70]
In vitro culture of human neutrophilsAntioxidantAnother potential therapeutic mechanism to treat endometriosis[68]
In vitro culture of endometrial cancer cellsGrowth inhibition and apoptosisCould be effective against endometrial hyperplasia and cancer[71]
ApigeninIn vitro culture of human cancer cell linesGrowth inhibition and apoptosis
VEGF inhibition		Could be effective against endometrial hyperplasia and cancer[74,75]
LuteolinHuman breast tumor xenografts in nude miceInhibition of tumor growth and angiogenesisCould be an adjuvant therapy of breast cancer[76,77]
NaringeninMouse model in vivoAnalgesic, anti-inflammatory and antioxidantCould be useful to treat chronic pelvic pain and its causes[78]
Rat model of hepatic injury in vivoAntifibroticCould be effective to treat uterine fibroids[79]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Greco, S.; Pellegrino, P.; Zannotti, A.; Delli Carpini, G.; Ciavattini, A.; Reis, F.M.; Ciarmela, P. Phytoprogestins: Unexplored Food Compounds with Potential Preventive and Therapeutic Effects in Female Diseases. Nutrients 2021, 13, 4326. https://doi.org/10.3390/nu13124326

AMA Style

Greco S, Pellegrino P, Zannotti A, Delli Carpini G, Ciavattini A, Reis FM, Ciarmela P. Phytoprogestins: Unexplored Food Compounds with Potential Preventive and Therapeutic Effects in Female Diseases. Nutrients. 2021; 13(12):4326. https://doi.org/10.3390/nu13124326

Chicago/Turabian Style

Greco, Stefania, Pamela Pellegrino, Alessandro Zannotti, Giovanni Delli Carpini, Andrea Ciavattini, Fernando M. Reis, and Pasquapina Ciarmela. 2021. "Phytoprogestins: Unexplored Food Compounds with Potential Preventive and Therapeutic Effects in Female Diseases" Nutrients 13, no. 12: 4326. https://doi.org/10.3390/nu13124326

APA Style

Greco, S., Pellegrino, P., Zannotti, A., Delli Carpini, G., Ciavattini, A., Reis, F. M., & Ciarmela, P. (2021). Phytoprogestins: Unexplored Food Compounds with Potential Preventive and Therapeutic Effects in Female Diseases. Nutrients, 13(12), 4326. https://doi.org/10.3390/nu13124326

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop